Physician profile
Adrian O Chen
NPI 1790952869
$3,385.65
in general payments reported to CMS, 2019-2025
33 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $430 · 2024: $1,427 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,385.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $402.18 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $364.26 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $351.81 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $346.79 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbott Laboratories | $318.85 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $187.27 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.38 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $179.74 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $148.39 | 2023-2025 | Rexulti |
| Pfizer INC. | $134.68 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $76.80 | 2023-2024 | Verquvo, Gardasil, Gardasil 9 |
| Novo Nordisk INC | $76.30 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $66.58 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $53.67 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.15 | 2023-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $43.73 | 2024 | Rexulti |
| Baxter Healthcare | $42.46 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Vertex Pharmaceuticals Incorporated | $37.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $37.50 | 2025 | |
| Antares Pharma, INC. | $35.61 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $33.91 | 2024-2025 | Voquezna |
| Tactile Systems Technology INC | $23.94 | 2025 | Nimbl, Flexitouch Plus |
| Glaxosmithkline, LLC. | $23.58 | 2023 | Shingrix, Arexvy |
| Hologic Sales and Service, LLC | $23.36 | 2025 | Thinprep 2000 Processor, Aptima |
| Neurocrine Biosciences, INC. | $22.03 | 2025 | |
| Amgen INC. | $19.99 | 2025 | Repatha, Otezla |
| Astellas Pharma US INC | $16.27 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.96 | 2025 | Xifaxan |
| Mylan Specialty L.P. | $15.27 | 2023 | Yupelri |
| Axsome Therapeutics, INC. | $14.81 | 2024 | Auvelity |
| Optinose US, INC. | $13.95 | 2024 | |
| Halozyme INC | $13.92 | 2023 | |
| Grifols USA, LLC | $13.55 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.